Evidence map›Paper›PMID 36146463›Full record

ReviewVaccines2022

Vaccines against Emerging and Neglected Infectious Diseases: An Overview.

Larissa Vuitika, Wasim A Prates-Syed, Jaqueline Dinis Queiros Silva, Karin P Crema, Nelson Côrtes, Aline Lira, Julia Beatriz Menuci Lima, Niels Olsen Saraiva Camara, Lena F Schimke, Otavio Cabral-Marques and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Editorial: Combatting tropical diseases: a multi-level approach.Frontiers in cellular and infection microbiology · 2024
    Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Microorganisms · 2022
    Review
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Larissa VuitikaDepartment of Immunology, Institute of Biomedical Sciences IV, University of São Paulo (ICB-IV/USP), São Paulo 05508-000, SP, Brazil.
Wasim A Prates-SyedDepartment of Immunology, Institute of Biomedical Sciences IV, University of São Paulo (ICB-IV/USP), São Paulo 05508-000, SP, Brazil.ORCID 0000-0002-2032-3902
Jaqueline Dinis Queiros SilvaLaboratory of Research in Infectious Diseases (LAPI), Hospital Prof. Edgard Santos, Federal University of Bahia, Salvador 40110-060, BA, Brazil.
Karin P CremaDepartment of Immunology, Institute of Biomedical Sciences IV, University of São Paulo (ICB-IV/USP), São Paulo 05508-000, SP, Brazil.
Nelson CôrtesDepartment of Immunology, Institute of Biomedical Sciences IV, University of São Paulo (ICB-IV/USP), São Paulo 05508-000, SP, Brazil.ORCID 0000-0002-6829-9075
Aline LiraDepartment of Immunology, Institute of Biomedical Sciences IV, University of São Paulo (ICB-IV/USP), São Paulo 05508-000, SP, Brazil.ORCID 0000-0001-9405-4955
Julia Beatriz Menuci LimaDepartment of Immunology, Institute of Biomedical Sciences IV, University of São Paulo (ICB-IV/USP), São Paulo 05508-000, SP, Brazil.ORCID 0000-0003-2369-9435
Niels Olsen Saraiva CamaraDepartment of Immunology, Institute of Biomedical Sciences IV, University of São Paulo (ICB-IV/USP), São Paulo 05508-000, SP, Brazil.ORCID 0000-0001-5436-1248
Lena F SchimkeDepartment of Immunology, Institute of Biomedical Sciences IV, University of São Paulo (ICB-IV/USP), São Paulo 05508-000, SP, Brazil.ORCID 0000-0002-5616-3410
Otavio Cabral-MarquesDepartment of Immunology, Institute of Biomedical Sciences IV, University of São Paulo (ICB-IV/USP), São Paulo 05508-000, SP, Brazil.ORCID 0000-0002-3183-6236
Mohammad SadraeianInstitute for Biomedical Materials and Devices (IBMD), Faculty of Science, University of Technology, Sydney, NSW 2007, Australia.ORCID 0000-0002-7384-2247
Lorena C S ChavesDepartment of Microbiology and Immunology, School of Medicine, Emory University, Claudia Nance Rollins Building, Atlanta, GA 30329, USA.ORCID 0000-0001-7515-0781
Gustavo Cabral-MirandaDepartment of Immunology, Institute of Biomedical Sciences IV, University of São Paulo (ICB-IV/USP), São Paulo 05508-000, SP, Brazil.

Funding

São Paulo Research Foundation 2019/14526-0São Paulo Research Foundation 2020/05146-7
6 · The paper itself

Abstract

Neglected Tropical Diseases (NTDs) are a group of diseases that are highly prevalent in tropical and subtropical regions, and closely associated with poverty and marginalized populations. Infectious diseases affect over 1.6 billion people annually, and vaccines are the best prophylactic tool against them. Along with NTDs, emerging and reemerging infectious diseases also threaten global public health, as they can unpredictably result in pandemics. The recent advances in vaccinology allowed the development and licensing of new vaccine platforms that can target and prevent these diseases. In this work, we discuss the advances in vaccinology and some of the difficulties found in the vaccine development pipeline for selected NTDs and emerging and reemerging infectious diseases, including HIV, Dengue, Ebola, Chagas disease, malaria, leishmaniasis, zika, and chikungunya.

Indexed as

emerging infectious diseasesneglected diseasesvaccines

Identifiers

PMID36146463
PMCPMC9503027

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.